Free Newsletter
SPOTLIGHT: Merck posts $1.6 billion loss
Merck reported a whopping $1.6 billion loss for the fourth quarter, mostly because of massive accounting charges related to its $4.85 billion Vioxx settlement. During the same period last year, Merck posted a $473.9 million profit. Meanwhile, some Florida patients left out of the Vioxx deal now want in. Report | Report
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
Click here to get the FiercePharma email newsletter for FREE!
Be the first to comment